Longduoduo Co Ltd
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct healthcare services and commissions earned as a sales agent for Inner Mongolia Honghai Health Management Co., Ltd. The business has shifted heavily toward agency commissions, making it more of a healthcare distribution and referral platform than a pure service clinic operator.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueIn-clinic or direct patient services such as autohemotherapy, assay, and PRP offerings.
Commission income earned from selling Honghai-administered preventive healthcare solutions.
Products
Reported · share of revenue- Commission Revenue97.2 %
- Service Revenue2.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company serves consumers in Inner Mongolia and nearby markets who purchase preventive or alternative healthcare services, often through local operating entities. A much larger share of revenue now comes from customers referred into Honghai's healthcare solutions, with Longduoduo acting as the sales agent and earning commissions. Demand appears sensitive to local economic conditions and discretionary health spending.
Individuals purchasing in-house healthcare services such as autohemotherapy, PRP, assay and related treatments.
Consumers who buy preventive healthcare solutions administered by Honghai, generating commissions for Longduoduo.
Households in Inner Mongolia and Beijing that spend on non-essential healthcare services when economic conditions allow.
Strategy
Management is focused on funding growth, improving operating policies, and balancing customer prepayments with working capital needs. The company also seeks access to U.S. public markets for financing, while continuing to rely on Honghai commissions as the main revenue engine. Its near-term strategy is defensive as well as expansionary: preserve liquidity, stabilize demand, and reduce dependence on a single relationship.
Growth depends on capital for expansion, but PRC listing approvals may delay or block fundraising.
The company has limited scale and needs cash generation to fund obligations and expansion.
Honghai commissions represent the vast majority of revenue, creating concentration risk.
Geography
Operations are concentrated in Inner Mongolia, China, with entities in Huhhot, Ulanqab, Baotou and Ordos, plus one entity in Beijing. The company also references U.S. capital markets as a funding source, but its operating revenue is generated in China, making it exposed to Chinese consumer demand and PRC regulatory conditions.
Risks
The biggest risk is customer and revenue concentration: most revenue comes from Honghai commissions, so any disruption to that relationship would materially hurt results. The company is also exposed to PRC regulatory approval risk for overseas listings and to weak consumer spending in China, which can reduce demand for discretionary healthcare services. As a small operator with limited scale, it also faces liquidity pressure, going-concern risk, and execution risk in trying to expand while revenue remains volatile.
- Dependence on Honghai commissionsImpact: CriticalLikelihood: High
Over 97% of annual revenue came from one sales agency relationship, so termination or repricing would sharply reduce income.
Exposure: Revenue and earnings concentration
- Going-concern and liquidity pressureImpact: HighLikelihood: High
The company expects to rely on operations, public offering proceeds or debt financing to fund growth and obligations.
Exposure: Cash flow and solvency
- PRC overseas listing approval riskImpact: HighLikelihood: Medium
Future financing through U.S. markets may require CSRC approval, which could be delayed or denied.
Exposure: Capital access
- Weak discretionary health spendingImpact: High
Management cited a softer economic environment and lower customer health expenditures.
Exposure: Demand and revenue volatility
- China regulatory and cybersecurity uncertaintyImpact: MediumLikelihood: Medium
PRC rules on overseas listings and data review could affect quotation and compliance costs.
Exposure: Regulatory compliance
Accounting
Judgemental itemsThe company recognizes both direct service revenue and agency commissions, so classification and timing affect reported growth and margins.
Impact: Revenue mix and gross profit
Material prepayments and deferred revenue indicate cash is received before services are delivered.
Impact: Working capital and revenue timing
Weak consumer spending and small-ticket healthcare sales can increase collection risk.
Impact: Receivables and earnings
Management explicitly cites impairment, contingencies and litigation as key estimates.
Impact: Potential earnings volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Akso Health Group
AHG · Services-Business Services, NEC
Akso Health Group is a U.S.-incorporated holding company with operating subsidiaries in the United States and China that sell medical devices and offer healthcare-related services.
Zhongchao Inc.
ZCMD · Services-Educational Services
Hongchang International Co., Ltd
HCIL · Electromedical & Electrotherapeutic Apparatus
Hongchang International Co., Ltd is a U.S.-listed group whose operating subsidiaries in Fujian Province sell meat and food products, install support…
Shineco, Inc.
Agricultural Production-Crops
Landbay Inc
LNBY · Gold and Silver Ores
Landbay Inc is a U.S.-incorporated company with its principal executive office in Hangzhou, China, that reports revenue from selling network equipment and providing online data marketing services.
Kun Peng International Ltd.
KPEA · Services-Educational Services
Last updated: 24/09/2026